Patents by Inventor Jay C Strum

Jay C Strum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK INHIBITORS
    Publication number: 20240109906
    Abstract: Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: March 13, 2023
    Publication date: April 4, 2024
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS
    Publication number: 20230302001
    Abstract: The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.
    Type: Application
    Filed: December 1, 2022
    Publication date: September 28, 2023
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jessica A. Sorrentino, Anne Y. Lai, Jay C. Strum, Patrick Joseph Roberts
  • Preservation of immune response during chemotherapy regimens
    Patent number: 11529352
    Abstract: The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: December 20, 2022
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jessica A. Sorrentino, Anne Y. Lai, Jay C. Strum, Patrick Joseph Roberts
  • Combination therapy for treatment of cancer
    Patent number: 11364222
    Abstract: Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular proliferation, including a cancer or a tumor.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: June 21, 2022
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay C. Strum, Gregory R. Thatcher, Rui Xiong, Jiong Zhao, Debra A. Tonetti
  • PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS
    Publication number: 20190321370
    Abstract: The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.
    Type: Application
    Filed: June 5, 2019
    Publication date: October 24, 2019
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jessica A. Sorrentino, Ann Y. Lai, Jay C. Strum, Patrick Joseph Roberts
  • COMBINATION THERAPY FOR TREATMENT OF CANCER
    Publication number: 20190321332
    Abstract: Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular proliferation, including a cancer or a tumor.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 24, 2019
    Applicants: G1 Therapeutics, Inc., The Board of Trustees of the University of Illinois
    Inventors: JAY C. STRUM, Gregory R. Thatcher, Rui Xiong, Jiong Zhao, Debra A. Tonetti
  • CDK inhibitors
    Patent number: 10189849
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: January 29, 2019
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 10189851
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: January 29, 2019
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 10189850
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: January 29, 2019
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK INHIBITORS
    Publication number: 20180201618
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK INHIBITORS
    Publication number: 20180201619
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK Inhibitors
    Publication number: 20180201617
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 9957276
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: May 1, 2018
    Assignee: GI Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
    Patent number: 9808461
    Abstract: The presently disclosed subject matter relates to methods and compositions for protecting cells and or tissues from damage due to ischemia. In particular, the presently disclosed subject matter relates to the protective action of cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to, or that are at risk of, ischemia.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: November 7, 2017
    Assignees: The University of North Carolina at Chapel Hill, G1 Therapeutics, Brigham and Women's Hospital
    Inventors: Derek P. DiRocco, Norman E. Sharpless, Jay C. Strum, John E. Bisi, Patrick J. Roberts, Benjamin D. Humphreys, Kwok-Kin Wong
  • CDK Inhibitors
    Publication number: 20170057971
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Applicant: G1 THERAPEUTICS, INC.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 9499564
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: November 22, 2016
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 9481691
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: November 1, 2016
    Assignee: G1 THERAPEUTICS, INC.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK Inhibitors
    Publication number: 20150246925
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: May 14, 2015
    Publication date: September 3, 2015
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK Inhibitors
    Publication number: 20150246926
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: May 14, 2015
    Publication date: September 3, 2015
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 9102682
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: August 11, 2015
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum